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Role of humoral presensitization in human renal transplant re-
jection. A prospective study of 31 cadaveric renal allograft recipi-
ents was performed to determine the significance of pre-
transplant presensitization undetected by the conventional mi-
crolymphocytotoxicity crossmatch. Donor-specific humoral
presensitization revealed by the antibody-dependent cell-mediat-
ed cytotoxicity assay (ADCC) was associated with a high in-
cidence of early graft rejection. Six-month graft survival was
20% in recipients with positive pretranspiant ADCC and 75% in
ADCC-negative recipients (P < 0.01). Among recipients highly
presensitized to a random panel of HLA antigens, donor-specific
humoral presensitization detected by chromium-5 1-release com-
plement-dependent cytotoxicity (51Cr-CDC) was also highly cor-
related with accelerated rejection (P <0.05). Pathologic study of
the rejected allografts revealed antibody-mediated rejection vascu-
litis in all recipients. We conclude that humoral presensitization
undetected by current conventional methods plays a cardinal
role in early renal graft rejection and is a major factor responsible
for low cadaveric renal transplant survival. This study suggests
that use of the ADCC and 51Cr-CDC as routine adjunctive cross-
match procedures may contribute to improvement in renal trans-
plant survival rates.
Role de Ia présensibilisation humorale dans le rejet du rein hu-
main transplanté. Une étude prospective de 31 receveurs de
reins de cadavres a ete realisée pour determiner Ia signification
de La prCsensibilisation antérieure a Ia transplantation, non dé-
tectée par Ia technique habituelle de microlymphocytotoxicite.
La présensibilisation humorale specifique du donneur révélée
par Ia mesure de cytotoxicité a mediation cellulaire dépendante
de l'anticorps (ADCC) a été associCe a one incidence élevée de
rejet précoce. La survie de Ia greffe a six mois était de 20% chez
les receveurs ayant one ADCC positive et de 75% chez les rece-
veurs négatifs (P < 0, 01). Parmi les receveurs fortement désen-
sibilisés a une série d'antigénes HLA, Ia presensibilisation hu-
morale spécifique du donneur detectée par Ia cytotoxicite dé-
pendante du complement (CDC) était aussi fortement corrélCe
au rejet accéléré (P < 0,05). L'étude morphologique des greffes
rejetées a montré chez tous les receveurs des lesions de vascula-
rite a mediation par les anticorps. Nous concluons que Ia présen-
sibilisation humorale non dCtectée par les méthodes convention-
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nelles joue un role essentiel dans le rejet précoce et constitue un
facteur responsable de faible survie des transplants. Cette étude
suggére que l'emploi de ADCC et de CDC en routine comme
épreuves de compatibilité pourrait contribuer a améliorer Ia sur-
vie des reins greffes.
Renal transplant survival rates in the United
States have exhibited a declining trend over the past
6 years [1]. This alarming finding has sparked re-
newed interest in the role of pretranspiant a!-
loimmunity in renal graft survival.
Early efforts to improve graft survival led to the
discovery that circulating antidonor antibodies de-
tected by the standard microlymphocytotoxicity
(complement-dependent cytotoxicity by eosin dye
exclusion) crossmatch were associated with hyper-
acute or accelerated rejection [2—5]. Thus, at the
present time, routine pretransplant assessment of
recipient ailoimmunity consists primarily of per-
formance of a standard crossmatch using recipient
serum and donor lymphocytes. Recipients are uni-
versally excluded from transplantation in the pres-
ence of a positive standard crossmatch. Despite this
restriction, 1-year cadaveric donor graft survival
rates remain approximately 50%. Because many of
the graft losses are due to antibody-mediated accel-
erated rejections occurring within the first 3 months
following transplantation, it is likely that the stan-
dard crossmatch may be inadequate in detecting re-
cipient presensitization to a specific donor. Indeed,
it has been demonstrated that several assays that
are not yet in widespread clinical use, includ-
ing lymphocyte-mediated cytotoxicity (LMC),
antibody-dependent cell-mediated cytotoxicity
(ADCC), and complement-dependent cytotoxicity
(CDC) utilizing chromium-Si release are capable of
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detecting antidonor alloimmunity even when the
standard crossmatch is negative [6— 10].
The following prospective study was performed
to determine the clinical significance of donor-spe-
cific presensitization as assessed by ADCC, LMC,
and CDC assays in renal allograft recipients with
negative standard crossmatches. Our results in-
dicate that pretransplant humoral alloimmunity, as
detected primarily by ADCC, is associated with
early graft rejection and that routine use of this as-
say may result in improved graft survival.
Methods
Thirty-one consecutive cadaveric renal trans-
plants performed at the Peter Bent Brigham Hospi-
tal from July 1976 to October 1977 were included in
the study. Twenty-five of these were first grafts, 5
were second grafts, and 1 was a third graft. In recip-
ients who had received a previous transplant, the
previous donors' antigens were avoided in the sub-
sequent transplant. Accurate transfusion histories
were unobtainable in the majority of patients. Prior
to transplantation, each recipient was screened
monthly for the presence of preformed anti-HLA-
A, anti-HLA-B, and anti-HLA-C locus antibodies
by testing the recipients' serum samples against a 40-
member panel selected to contain all known HLA-
A, HLA-B, and HLA-C locus antigens. A standard
(NIH) eosin dye microlymphocytotoxicity assay
was used. Each known HLA antigen was represent-
ed two to five times on the screening panel. Reactiv-
ity against 10% or more of the screening panel mem-
bers indicated significant presensitization (panel
presensitization). All recipients had negative stan-
dard crossmatches against their specific donors
when we used the most recent serum samples. In
the case of presensitized recipients, at least three of
their most reactive past serum samples were tested
also against the specific donor. In addition, a modi-
fication of the standard crossmatch that uses sub-
lytic amounts of rabbit antihuman thy mocyte globu-
lin (ATG), to increase the sensitivity of the assay
(ATG crossmatch, see below), was negative in all
recipients. Highly sensitized recipients were
screened also for nonspecific cytotoxicity by testing
against recipient cells.
Three assays, LMC, ADCC, and CDC, were per-
formed in addition to the standard NIH and ATG
crossmatches with only recipient blood obtained
immediately prior to transplantation. These assays
used chromium-S 1-labeled lymphocytes from the
specific donor as target cells. These studies were
performed to determine donor-specific alloimmu-
nity rather than degree of presensitization and,
thus, were not used as screening procedures. The
transplant team responsible for the care of the re-
cipients was not apprised of the results of the pre-
transplant LMC, ADDC or 51Cr-CDC. Trans-
plantation was performed on the basis of negative
standard NIH and ATG crossmatches, regardless of
the results of the LMC, ADCC, or 51CR-CDC as-
says. Followup data was available in all recipients
for up to 6 months following transplantation. Graft
failure indicated that irreversible rejection necessi-
tating return to dialysis had occurred within 6
months after transplant, whereas virtually all recipi-
ents classified as having functioning grafts had
serum creatinine concentrations less than 2 mg/dl at
6 months. Histologic studies were performed on 19
biopsy specimens and on 16 nephrectomy speci-
mens in 28 recipients. Techniques were as follows.
Standard (NIH) and ATG crossrnatch. Micro-
lymphocytotoxicity crossmatch trays containing
the most recent serum of every potential recipient
were prepared and frozen monthly. At the time of
donor crossmatch, trays of ABO-compatible recipi-
ents' serum samples were thawed for use.
The initial crossmatch was performed as follows:
each iS-pi well contained 1 pJ of recipient or con-
trol serum. A cytotoxic dilution of rabbit ATG was
used as postive control, and both normal human
serum (NHS) and donor serum were used as neg-
ative controls.
Lymphocytes from donors' lymph nodes or
spleens were prepared by centrifugation over a Fi-
coll-Hypaque density gradient. The cells were then
adjusted to a concentration of 1.5 x 106 cells/ml.
One microliter of donor cells was added to each
well and trays incubated for 30 mm at 22° C. After
incubation, 5 l of rabbit complement was added to
each well, and the tray incubated for an additional
60 mm at 22° C. Following this incubation, 5 pJ of
5% eosin dye was added. After 2 mm 8 l of formal-
dehyde was added. A coverslide was placed on the
tray, sealed with melted petrolatum, and the reac-
tions were read under an inverted phase contrast
microscope.
Recipients who had a negative crossmatch with
this technique were then recrossmatched. Only re-
cipients who had a negative initial crossmatch and
no evidence of previous presensitization to donor
antigens by computer analysis of previous screen-
ing specificities (see below) were considered for fi-
nal crossmatch.
The final crossmatches for each recipient were
performed as follows. The most recent recipient
640 Gailiunas et at
serum sample, as well as three or more most reac-
tive past sera were tested. One microliter of serum,
as well as serial dilutions of 1/2, 1/4, and 1/8 of each
serum sample to be tested, was placed in individual
wells of a microlymphocytotoxicity tray. One mi-
croliter of donor cells was then added, and the tray
was incubated for 30 mm at 22° C. Two sets of sera
samples and cells were prepared in this fashion.
Following the 30-mm incubation, 5 il of rabbit com-
plement was added to each well of the first set. To
each well of the second set was added 5 jl of rabbit
complement containing a sublytic dilution of rabbit
ATG. Both sets were then incubated for an addi-
tional 60 mm at 22° C. The plates were then stained
and fixed, and reactions were read as described
above.
Computer analysis of presensitization. To avoid
antigens to which the recipient was previously sen-
stized, we used a computer program to analyze the
antibody specificities in the screening sera. This
program has been described in detail elsewhere
[11]. Briefly, the analysis begins by gathering into a
matrix all of the reactions between the serum being
analyzed and the 40 screening panel members. In
assessing the evidence for each specificity, the pro-
gram refers to decision tables developed by labora-
tory staff members. The decision table assigns a
score to each specificity based on the number of
positive and negative reactions, and the one with
the highest score is selected on each pass through
the analysis logic. When no more specificities can
be identified, the list of analyzed antibodies is
stored in the patient's screening history file. The
program combines each new screening analysis
with previous analyses to update the cumulative list
of presumed specificities. In the present study, pa-
tients were crossmatched and considered for trans-
plantation only if they had no previously identified
antibodies to donor antigens by this analysis.
Target cells for chromium-51-release assay.
Lymphocytes were prepared as a described else-
where [12]. Briefly, lymphocytes were obtained
from the spleens of cadaveric donors by centrifuga-
tion over a Ficoll-Hypaque density gradient, la-
beled with chromium-5l, washed three times, ad-
justed to 1 x l0 cells/mi for LMC and ADCC or
2 x 10 cells/ml for CDC.
Lymphocyte-in ediated cytotoxicity (LMC). The
technique of LMC, ADCC, and CDC has been pre-
viously described in detail [12]. Recipient blood
samples were obtained immediately prior to trans-
plantation. Lymphocytes were separated by centri-
fugation over Ficoll-Hypaque, washed, and resus-
pended in RPMI-l640 with 10% NHS at 5 x 106
cells/mi. Lymphocytes from two to three normal in-
dividuals were prepared in the same manner for use
as controls. All assays were performed in microtiter
plates in quadruplicate. One hundred microliters of
patient or control lymphocyte were added to 50 sl
of chromium-S 1-labeled target cells and 50 si of
RPMI. Plates were centrifuged at X55g for 5 mm
and incubated at 37° C for 4 hours. The plates were
then centrifuged at x500g for 10 mm at 4° C. One
hundred microliters of supernatant was harvested
and counted in a liquid scintillation system. Maxi-
mum releasable counts were obtained by incubating
target cells in distilled water for 4 hours at 37° C.
Antibody-dependent cell-mediated cytotoxicitv
(ADCC). The same lymphocytes that were used as
controls in the LMC were used as pooled normal
effectors (PNE) in the ADCC. Fifty microliters of a
1/25 dilution of recipient or control heat-inactivated
serum was added to 50 pi of chronium-5 1-labeled
target cells and 100 i of PNE at 5 x 106 cells/mI.
representing a final serum dilution of 1/100. Plates
were centrifuged, incubated, harvested, and
counted as in the LMC.
Complement-dependent cytotoxicity (C'Dc.).
Twenty-five microliters of recipient or control
serum were added to 25 l of chromium-S 1-labeled
target cells and incubated for 1 hour at 22° C. Twen-
ty-five microliters of rabbit complement was then
added, and the cells were incubated for an addition-
al 1 hour at 22° C. Maximum releasable counts were
obtained by incubation of 25 ,al of a 1/30 dilution of
rabbit antihuman thymocyte globulin with 25 pA of
target cells and 25 pA of NHS. Following in-
cubation, 125 pA of cold RPMI-1640 was added.
Plates were centrifuged at xSOOg for 10 mm at 4° C.
One hundred microliters of supernatant was then
harvested and counted.
Percent specific chromium-Si release (%SCR) for
each assay was calculated as follows:
%SCR =
cpm (experimental) — cpm (control) >< 100
cpm (maximum release) — cpm (control)
A %SCR of 5% or greater with a statistical signifi-
cance of greater than 95% (Student's t test) was
considered positive.
Pathology studies. Multiple sections of each allo-
graft biopsy specimen and nephrectomy specimen
were evaluated for the presence of arteritis. Arteri-
tis was classified as acute (fibrinoid necrosis in the
media), subacute (endothelial and intimal prolifera-
tion), and chronic (intimal fibrosis). The presence of
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each of these three forms of arteritis was sub-
jectively scored on a 0 to 4+ scale, based on the
proportion of arteries involved, the intensity of lo-
cal injury, and the overall degree of vascular lumi-
nal narrowing. For immunofluorescent studies, tis-
sue specimens were quick-frozen in dry ice and ace-
tone and stored in isopentane at _200 C, and
cryostat sections were stained with fluorescent la-
beled goat antisera to human IgG, 1gM, IgA, C3
(third component of complement), fibrinogen, and
albumin (Cappel Laboratories) by using standard
techniques. The procedure for scoring of immuno-
fluorescent deposits in arteries was similar to that
described for histologic evaluation.
Results
Six-month graft survival was 48% for recipients
of these 31 cadaveric kidneys. All subsequent graft
survival rates referred to indicate a 6-month surviv-
al. No statistically significant relationship emerged
between the degree of screening-panel reactivity
and graft outcome, although patients who were pre-
sensitized to 10% or more of the screening panel
tended to have a lower graft survival rate than those
recipients who were not significantly presensitized.
Presensitization to the specific donor as assessed
by the ADCC assay, however, was highly signifi-
cant by the x2 analysis as shown in Table 1. Patients
who had evidence of specific antidonor humoral al-
loimmunity detected by ADCC had only a 20% graft
survival at 6 months, whereas ADCC-negative re-
cipients had a 75% graft survival rate (P < 0.01).
The mean %SCR + SEM for ADCC-positive indi-
viduals who lost their grafts was 26.4 7.6%, sig-
nificantly greater than the mean 1.8 0.6% SCR
(P < 0.0001) for ADCC-negative recipients.
There was no significant association found be-
tween ADCC reactivity and panel presensitization.
Eighty-seven percent of the ADCC-positive cadav-
eric recipients were presensitized to a screening
panel, and 56% of the ADCC-negative cadaveric re-
cipients were also presensitized to a screening panel
(P = NS). There were comparable degrees of HLA
matching or mismatching for donor antigens among
both ADCC-positive and ADCC-negative recipi-
ents. Eleven of fifteen (73%) ADCC-positive and
ten of sixteen (63%) ADCC-negative individuals re-
ceived less than a two-antigen match. Five of fifteen
(33%) ADCC-positive and seven of sixteen (44%)
ADCC-negative recipients had 0-antigen matches.
Within the group of recipients who were panel-
presensitized, graft survival was significantly de-
pendent on evidence of donor-specific pre-
Table 1. Pretransplant donor-specific antibody-dependent cell-
mediated cytotoxicity (ADCC) and graft outcome
Graft losta Graft functioningb
ADCC positive 12 3
ADCC negative 4 12
a Patient returned to dialysis by 6 months.
b Serum creatinine was < 2 mg/dl at 6 months.
P <0.01, compared with recipients who were ADCC posi-
tive.
Table 2. Correlation of donor-specific ADCC with graft outcome
in panel-presensitized recipientsa
Graft lost Graft functioning
ADCC positive 11 2
ADCC negative 3 6b
a Presensitized to  10% of the members of a random screen-
ing panel by eosin-dye microlymphocytotoxicity
P <0.05, compared with recipients who were ADCC posi-
tive.
Table 3. Presensitization detected by lymphocyte-mediated
cytotoxicity (LMC) and complement-dependent cytotoxicity
(51Cr-CDC) and graft outcome
Graft lost Graft functioning
LMC positive 4 6
LMC negative 12
CDC positive 10 8
CDC negative 6 7
a P = NS.
sensitization (Table 2). Panel-presensitized recipi-
ents who also had a positive ADCC achieved only a
15% graft survival, whereas panel-pre sensitized re-
cipients with a negative ADCC achieved a 66% graft
survival (P < 0.05).
Recipients of second grafts in this series did well.
Four of five in whom this was a second transplant
had a negative ADCC and enjoyed good function.
One recipient of a second graft and one recipient of
a third graft had a positive ADCC (38 and 100%
SCR, respectively). Both experienced vigorous
early rejections.
Individually, neither lymphocyte-mediated cyto-
toxicity (LMC) nor complement-dependent cyto-
toxicity (CDC) correlated with graft outcome (Table
3). Nevertheless, among panel-presensitized cadav-
eric recipients who also had a positive donor-spe-
cific CDC, graft survival was significantly lower
(23%) than among recipients who had either panel-
presensitization or a positive CDC (66%) (P < 0.05)
(Table 4). In addition, there were nine panel pre-
sensitized recipients with both positive donor-spe-
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cific ADCC and CDC reactions who had significant-
ly reduced graft survival (22%) compared to five
panel-presensitized recipients with 100% graft sur-
vival who had neither a positive ADCC nor a CDC
(P < 0.025).
HLA matching appeared to be of some benefit,
primarily among those recipients who had signifi-
cant panel-presensitization. Graft survival was only
15% for 13 panel-presensitized recipients who re-
ceived less than a two-antigen matched graft but
was 67% among 9 panel-presensitized recipients
who received a two-antigen match or better
(P < 0.05).
Diagnostic biopsy samples were available from 19
of the 31 cases studied. The morphologic data are
summarized in Table 5, according to the results of
the pretranspiant ADCC and CDC assays. It is of
interest to note that all of the recipients with a posi-
tive pretransplant ADCC and/or CDC assay re-
quired diagnostic biopsy at a mean of 24 days after
transplantation, whereas recipients with com-
parable degrees of vascular injury in the ADCC-
negative, CDC-negative group did not require
biopsy until a mean of 58 days after transplantation.
Of these 19 biopsies, 16 showed mild intimal prolif-
Table 4. Correlation of 51Cr-CDC and panel presensitization with
graft outcome









a P <0.05, compared with recipients who were CDC positive
and panel positive.
erative lesions. In two instances, the proliferative
lesions were associated with early intimal fibrosis.
Focal acute necrotizing arteritis was found in 5 of
the 12 cases that had a positive pretransplantation
CDC assay. Tissue for immunofluorescent studies
was available from 14 of the 19 cases. Mural IgG
deposits were observed in the arteries of 5 cases
and 1gM deposits in 8 of the cases. 1gM deposits
were always more intense than those of IgG. These
deposits were all generally weak and focal except in
the ADCC-negative, CDC-positive groups where
histologic vasculitis was also more prominent.
Of the 19 grafts, 16 failed, and of the 16 failures,
nephrectomy specimens were available from 12. All
12 specimens showed moderate to severe arteritis,
which was inconsistent with further graft survival.
Arteritis in these cases consisted of various combi-
nations of the acute necrotizing, subacute prolifera-
tive, and chronic fibrosing forms. Of the 12 cases,
10 showed moderate to marked immunoglobulin de-
posits in arterial walls. 1gM deposits were most in-
tense. Again, it is interesting to note that of the cas-
es that were ADCC-positive before transplan-
tation, those that were also CDC-positive had
failed earlier than those that were CDC-negative. Of
the cases that were ADCC-negative, those that
were CDC-positive failed soon after the initial
biopsy and showed a very rapid progression of the
vascular lesions and the antibody deposits within 1
week, whereas the single case that was CDC-nega-
tive did not develop comparable arteritis and graft
failure until the fourth month.
These findings indicate that specific antidonor hu-
moral alloimmunity prior to transplantation is asso-




















necrosis proliferation fibrosisADCC CDC Panel
+ + + 9 26
Initial diagnostic biopsy
3 8 1 1+ 2/5 3/5 1+
+ — + 5 26 0 4 0 1+ 0/5 2/5 Tr+
— + + 3 21 2 2 0 2+ 2/2 2/2 3+
— — +1— 2 58 0 2 I
Nephrectomies or graft failures'
1+ 1/2 1/2 1+
+ + + 7 52 3/6 6/6 6/6 4+ 4/6 4/6 1+
+ — + 5 85 2/3 3/3 3/3 4+ 2/3 3/3 3+
— + + 3 27 2 2 2 5+ 2/2 2/2 4+
— — +/— 1 138 1 1 1 5+ 1 1 1+
Sum of the histologic scores for acute, subacute, and chronic arteritis
Sum of the scores for IgG and 1gM
Mean day after transplantation also includes day that irreversible rejection was evident even though nephrectomy specimen was not
available.
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ciated with earlier rejection and requirement for
biopsy. The greater the range of in vitro reactivity
in given assays, the more rapid the intensity and
progression of the vascular lesions and graft failure.
Discussion
Our results indicate that undetected pre-
sensitization in the form of humoral alloimmunity to
the donor plays an important role in early allograft
rejection. The importance of pretransplant testing
of recipients by means more sensitive than the stan-
dard crossmatch is emphasized.
It would seem that recipients immunized to a pool
of HLA antigens (presensitized recipients) would be
more likely to have antibodies, albeit not detectable
by the standard crossmatch, to any given donor
and, thus, would be more likely to undergo early
graft rejection. In our group of cadaveric recipients
presensitized to a panel of HLA antigens, a 6-month
graft survival was somewhat lower than that of non-
presensitized recipients. This trend is in agreement
with the findings of several previous studies, total-
ing 4,700 recipients [13—16], and suggests that the
standard crossmatch may often fail to detect donor-
specific antibodies.
Neither HLA-A and HLA-B locus-matching nor
mismatching appeared to be related to graft out-
come in presensitized and nonpresensitized cadav-
eric recipients taken as a whole. Previously report-
ed data on the role of HLA matching in graft surviv-
al is conflicting. Patel et al found no association
[17], but others have described significant dif-
ferences in survival between the best and the worst
matches [18, 19], and others have reported in-
conclusive results [1, 13]. We did, however, find a
significant correlation between HLA matching and
graft outcome in panel-presensitized cadaveric re-
cipients. Six-month graft survival was only 15% in
panel-resensitized cadaveric recipients who re-
ceived less than a two-antigen matched graft but
was 66% in presensitized recipients who received a
two-antigen match or better. In contrast, neither
HLA matching nor mismatching appeared to play a
role in graft survival in nonpresensitized recipients.
This is in agreement with data gathered by Opelz,
Mickey, and Terasaki [13] and suggests that the ef-
fect of undetected presensitization may be avoided
when antigens to which it may be directed are
matched.
Quite apparent was the high degree of correlation
between a positive pretransplant ADCC and graft
loss within 6 months. Patients with a positive
ADCC had 6-month survival rates of 20%, whereas
ADCC-negative recipients had a 6-month graft sur-
vival of 75%. An improved survival rate was also
apparent in the high-risk group of recipients who
were presensitized to the random lymphocyte-
screening panel, provided their donor-specific
ADCC was negative. Furthermore, recipients who
had additional evidence of donor-specific pre-
sensitization on the basis of both positive ADCC
and CDC assays had significantly lower graft sur-
vival rates (22%) than recipients who had neither
assay positive (100%).
Several investigators have attempted to improve
the sensitivity of the complement-dependent dye-
exclusion crossmatch by various modifications, in-
cluding the use of ATG in the crossmatch, as done
in the present study. Ferguson et al indicate that the
addition of rabbit antihuman IgG antiglobulin to the
crossmatch increases the sensitivity of the assay
and excludes sensitized recipients [20]. In their
study, they report on transplant results from 1970 to
1975, although the standard NIH technique was
used from 1970 to 1973 and the antiglobulin modifi-
cation was added thereafter. In addition, they began
at the time that the antiglobulin modification was
added to test numerous past sera, as well as the
most recent serum. Furthermore, no improvement
in graft survival is shown for this interval, and no
separate graft outcomes for 1970-1973 and 1973-
1975 are given. Cross et al have shown a 54% graft
survival rate with both the antiglobulin technique
and the additional modification of extending the du-
ration of the crossmatch to 3 hours (long incubation
crossmatch) [21]. This rate of success is seen in a
number of centers without use of these techniques.
Fuller, Cosimi, and Russell report improved graft
survival with ATG and antiglobulin techniques [22].
A comparison of the ATG versus the antiglobulin
CDC showed that of 272 reactions, 128 (47%) were
positive with either ATG or antiglobulin alone, 79
(29%) were positive with ATG but negative with
antiglobulin, and 21(8%) were negative with ATG
but positive with antiglobulin. A modification incor-
porating both reagents in a single assay yielded 44
(16%) positive reactions that were negative when ei-
ther reagent was used alone. Thus, the total false-
negative incidence for the ATG crossmatch was
24%, whereas that for the antiglobulin crossmatch
was 45%. One would conclude from this study that
the ATG modification appears to be more sensitive
than the antiglobulin technique is. In Fuller's study,
the success rate prior to the addition of the new
techniques (pre-1975) is compared to subsequent
success rate (1975—1977), not a truly comparable
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control group. In 1975. they began to crossmatch by
using all reactive past sera samples from each pa-
tient and added the new techniques simultaneously.
Which maneuver resulted in improvement in graft
survival (neglecting the fact that the control group
was historical) is unclear. None of these studies
prove that modifications of the dye-exclusion assay
improve its sensitivity. In each case, other variables
were introduced, making it difficult to attribute im-
proved graft outcome solely to changes in the as-
say.
Because the ADCC and 51Cr-CDC assays were
positive when the standard NIH and ATG eosin-
dye crossmatches failed to reveal presensitization,
they seem to be more sensitive techniques. Al-
though in this study no comparison was made with
an antiglobulin assay, an increase in sensitivity by
using 51Cr-ADCC and 51Cr-CDC rather than dye-ex-
clusion techniques may arise from several factors.
First, the chromium-SI-release permits more objec-
tive assessment of cytotoxicity, whereas the usual
dye exclusion reactions require subjective inter-
pretation, and therefore results vary with the expe-
rience of the observor. Second, the use of chro-
mium 51 as a marker of cell injury, particularly in
the ADCC, apparently makes lesser degrees of cell
membrane damage discernable than is revealed
with vital dyes. Our findings in this regard are in
agreement with those of several other studies in-
dicating that the chromium-SI-release ADCC assay
detects presensitization in the presence of negative
dye exclusion crossmatches [6, 23—25]. Third, the
ADCC assay is known to be capable of detecting at
least tenfold lower concentrations of IgG antibody
than is the eosin-dye cytotoxicity assay. This sensi-
tivity stems as much from the mechanism of cytol-
ysis involved in this system as from the use of the
radioactive marker. The assay relies on the ability
of a subpopulation of nonsensitized nonthymic-de-
pendent Fc receptor-bearing lymphocytes ("K"
cells) normally present in the circulation to mediate
killing of antibody-coated cells by a non-
complement-requiring mechanism [26-28]. Attach-
ment by the K cell to the Fc portion of an IgG anti-
body coating the target cell triggers its cytotoxic ac-
tivity. Finally, it is significant that the ADCC is
capable of detecting noncomplement fixing anti-
bodies not revealed by chromium 51 or eosin-dye
CDC [29]. ADCC mediates cytotoxicity of all four
subclasses of IgG, but complement is not fixed by
either IgG subclass 2 or 4 [27].
Our data regarding correlation of pretranspiant
ADCC positivity with early graft rejection confirms
the findings of a number of previous studies [23, 24,
30, 31]. Perhaps the delay in accumulating evidence
of the efficacy of this assay stems from variations in
techniques that limit realization of the full potential
of this assay. Specific donor cells rather than surro-
gate target cells chosen solely on the basis of HLA-
A and HLA-B locus similarity should be used. Sur-
rogate cells often are not identical with the donor
cell for other (minor) transplantation antigens that
may be responsible for graft rejection under re-
stricted circumstances (that is, HLA identical sib-
lings). Second, lymphocytes from sensitized recipi-
ents should not be used as effector cells because
they may often contain cytotoxic T cells, resulting
in cell-mediated killing of target cells, which may
mask ADCC reactivity. Although either unstimu-
lated lymphocytes or phytohema gluttinin (PHA)
-stimulated blasts may be used as target cells, it is
important to recognize that PHA blasts may result
in autokilling and thus yield either false-negative or
false-positive results [32]. Finally, it is imperative
to avoid false-negative results due to a prozone
phenomenon that may occur in the presence of high
antibody concentrations by using very dilute (1/50
to 1/1000) serum concentrations or by incubating
serum and target cells and washing off excess anti-
body prior to the addition of effector cells.
The antigen specificity of the antibody detected
by the ADCC assay in our patients cannot be dis-
cerned from the data presented. Inasmuch as this
assay can be used to detect anti-HLA-A, -B, or -c
locus antibodies, anti-B cell ("Ia-like") antibodies
or non-HLA-related antibodies, all possibilities
must be considered. Anti-HLA-A and -B locus anti-
bodies have been well-documented as a cause of
early graft loss [2]. In addition, non-HLA linked
(minor) antigens are thought to be responsible for
many graft failures among HLA-A, -B, -C, and -D
locus identical siblings. In this respect, it is possible
that the "false-positive" assays in our study detect-
ed antidonor alloimmunity not detrimental to graft
function (see below). Several studies have sug-
gested that ADCC reactivity may be present, either
before or after transplant, in recipients without evi-
dence of rejection [33, 34]. It is postulated that such
antibodies may, in fact, act as enhancing anti-
bodies. This issue will require more extensive eval-
uation of the specificities of the antibodies detected.
The significance of sensitization against B-cell-re-
stricted antigens also remains a controversial issue
at the present time. We have shown that the pre-
transplant presence of B-cell antibodies detected by
the EA rosette inhibition test (Fc receptor blocking
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assay) is associated with early graft rejection [35].
Terasaki et al have suggested that cytotoxic B-cell
antibodies reactive at 37° C ("warm antibodies")
may likewise be detrimental to graft function [36].
Other investigators have found no adverse effect of
presensitization to B-cell antigens or even suggest
an enhancing effect on graft survival [37-39]. The
majority of the noninjurious B-cell antibodies may,
in fact, be cold (4° C) reactive autoantibodies. In
any event, ADCC has been shown to be capable of
detecting anti-B cell antibodies [40, 41]. It is thus
conceivable that positive ADCC assays in recipi-
ents who lose their grafts may detect anti-}{LA-A
or -B locus or deleterious anti-"Ia like" antibodies,
whereas "false"-positive results may occur due to
the presence of the cold reactive possibly enhancing
autoantibody directed to other B-cell antigens. As
noted above, the present study does not discern
anti-T-cell from anti-B-cell antibodies, because
spleen, containing roughly 50% T and 50% B cells,
was the source of the target cells. It has now be-
come routine for many laboratories to perform
screening and crossmatching on purified T and B
cells. This practice may help clarify the significance
of anti-B-cell antibodies.
The mechanism whereby the ADCC or CDC pro-
cess mediates rejection is as yet undefined. Of clini-
cal relevance is the observation that antibodies
eluted from rejecting kidneys following transplant
nephrectomy are capable of mediating donor-spe-
cific ADCC [42]. In this study, we have shown the
presence of active arteritis in virtually all rejecting
allografts. The majority of these grafts revealed
mural vascular immunoglobulin deposits associated
with fibrinoid necrosis of the vascular media at ne-
phrectomy. These observations suggest that the
ADCC is not only a valuable assay of humoral pre-
sensitization but may also be implicated as an inter-
esting and significant mechanism of renal allograft
rejection.
Summary'. Several lines of evidence indicate that
undetected humoral presensitization plays an im-
portant role in early renal allograft rejection. First,
nonspecific panel presensitization tends to be asso-
ciated with accelerated rejections. Second, better
HLA matching appears to improve graft survival in
panel-presensitized recipients. Third, humoral pre-
sensitization to the specific donor can be detected
by both the ADCC and CDC in recipients with neg-
ative standard NIH and ATG crossmatches, and
this type of donor specific alloimmunity is associat-
ed with a high incidence of early graft rejections.
Finally, pathologic study of renal graft tissue from
these recipients reveals prominent rejection vascu-
litis with mural immunoglobulin deposition.
Routine clinical application of the ADCC and
51Cr-CDC as adjunctive crossmatch assays, in addi-
tion to the antiglobulin and ATG assays, will im-
prove the identification of recipients at high risk of
rejecting a given allograft and thereby may contrib-
ute to improved renal transplant survival rates. In
addition, detailed studies of the nature and specific-
ity of the antibodies detected will provide important
insights into the mechanisms of human allograft re-
jection.
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